Top

Annals of Surgical Oncology

Published in:

01-05-2011 | Endocrine Tumors

Characteristics of Primary Papillary Thyroid Carcinoma with False-Negative Findings on Initial ¹⁸F-FDG PET/CT

Authors: Jin Woong Choi, MD, Young Hoon Yoon, MD, Yeo Hoon Yoon, MD, Seong Min Kim, MD, Bon Seok Koo, MD

Published in: Annals of Surgical Oncology | Issue 5/2011

Abstract

Background

We often observe that uptake of tracer is not detected in the primary cancer focus in patients with histologically proven papillary thyroid carcinoma (PTC) on preoperative ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography (¹⁸F-FDG PET/CT). Therefore, we analyzed the clinical and pathologic variables affecting false-negative findings in primary tumors on preoperative ¹⁸F-FDG PET/CT.

Methods

We retrospectively reviewed the medical records of 115 consecutive patients who underwent ¹⁸F-FDG PET/CT for initial evaluation and were diagnosed with PTC by postoperative permanent biopsy. The clinical and pathologic characteristics that influence the ¹⁸F-FDG PET/CT findings in these patients were analyzed with respect to the following variables: age, gender, tumor size, multifocality of the primary tumor, perithyroidal invasion, lymphovascular or capsular invasion, and central lymph node metastasis-based final pathology.

Results

Twenty-six (22.6%) patients had false-negative ¹⁸F-FDG PET/CT findings. In patients with negative ¹⁸F-FDG PET/CT findings, tumor size, and perithyroidal and lymphovascular invasion were significantly less than in patients with positive ¹⁸F-FDG PET/CT findings. Tumors >1 cm in size were correlated with ¹⁸F-FDG PET/CT positivity. On multivariate analysis, perithyroidal invasion (P = 0.026, odds ratio = 7.714) and lymphovascular invasion (P = 0.036, odds ratio = 3.500) were independent factors for ¹⁸F-FDG PET/CT positivity. However, there were no significant differences between ¹⁸F-FDG PET/CT positivity and age, gender, capsular invasion, and central lymph node metastasis based on final pathology.

Conclusions

Tumor size and perithyroidal and lymphovascular invasion of papillary carcinoma can influence ¹⁸F-FDG PET/CT findings. Absence of perithyroidal and lymphovascular invasion were independent variables for false-negative findings on initial ¹⁸F-FDG PET/CT in patients with PTC.

Pace L, Nicolai E, Klain M, et al. Diagnostic value of FDG PET/CT imaging. Q J Nucl Med Mol Imaging. 2009; 53(5):503–12.PubMed

Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004; 22(21):4357–68.PubMedCrossRef

Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003; 44(8):1200–9.PubMed

Bertagna F, Bosio G, Biasiotto G, et al. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Clin Nucl Med. 2009; 34(11):756–61.PubMedCrossRef

Chung J, So Y, Lee J, et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 1999; 40(6):986.PubMed

Razfar A, Branstetter BFt, Christopoulos A, et al. 2010 Clinical usefulness of positron emission tomography-computed tomography in recurrent thyroid carcinoma. Arch Otolaryngol Head Neck Surg 136(2): 120–5.PubMedCrossRef

Zuijdwijk MD, Vogel WV, Corstens FH, et al. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma. Nucl Med Commun. 2008; 29(7):636–41.PubMedCrossRef

Jeong HS, Chung M, Baek CH, et al. Can [18F]-fluorodeoxyglucose standardized uptake values of PET imaging predict pathologic extrathyroid invasion of thyroid papillary microcarcinomas? Laryngoscope. 2006; 116(12):2133–7.PubMedCrossRef

Mitchell JC, Grant F, Evenson AR, et al. 2005 Preoperative evaluation of thyroid nodules with 18FDG-PET/CT. Surgery 138(6): 1166–74, discussion 1174–5.PubMedCrossRef

10.

Luster M, Karges W, Zeich K, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010; 20(5):527–33.PubMedCrossRef

11.

Esteva D, Muros MA, Llamas-Elvira JM, et al. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer. Ann Surg Oncol. 2009; 16(7):2006–13.PubMedCrossRef

12.

Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167–214.PubMedCrossRef

13.

NCCN. NCCN Clinical Practive Guidelines in Oncology: thyroid carcinoma Available: http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf. Accessed 14 Oct 2010.

14.

Gharib H, Papini E, Paschke R, et al. American association of clinical endocrinologists, Associazione Medici Endocrinologi, and European thyroid association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. Endocr Pract. 2010; 16(3):468–75.PubMed

15.

Giammarile F, Hafdi Z, Bournaud C, et al. Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake? Eur J Endocrinol. 2003; 149(4):293–300.PubMedCrossRef

16.

Menzel C, Zaplatnikov K, Diehl M, et al. The influence of thyroglobulin on functional imaging in differentiated thyroid cancer. Nucl Med Commun. 2004; 25(3):239–43.PubMedCrossRef

17.

Schluter B, Bohuslavizki KH, Beyer W, et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med. 2001; 42(1):71–6.PubMed

18.

Puxeddu E, Filetti S. The 2009 American thyroid association guidelines for management of thyroid nodules and differentiated thyroid cancer: progress on the road from consensus-to evidence-based practice. Thyroid. 2009; 19(11):1145–7.PubMedCrossRef

19.

Tuttle RM, Leboeuf R, Martorella AJ. Papillary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am. 2007; 36(3):753–78, vii.PubMedCrossRef

Title: Characteristics of Primary Papillary Thyroid Carcinoma with False-Negative Findings on Initial 18F-FDG PET/CT
Authors: Jin Woong Choi, MD
Young Hoon Yoon, MD
Yeo Hoon Yoon, MD
Seong Min Kim, MD
Bon Seok Koo, MD
Publication date: 01-05-2011
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 5/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-010-1469-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Characteristics of Primary Papillary Thyroid Carcinoma with False-Negative Findings on Initial ¹⁸F-FDG PET/CT

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2011

Sequential Transcatheter Arterial Chemoembolization and Portal Vein Embolization versus Portal Vein Embolization Only before Major Hepatectomy for Patients with Hepatocellular Carcinoma

Influence of A9 Region Mutation in EphB2 Gene in the Prognosis of Patients with Colorectal Adenocarcinoma

Using Gene Expression Profiling to Predict Response and Prognosis in Gastrointestinal Cancers—The Promise and the Perils

To Supplement or Not to Supplement: A Cost-Utility Analysis of Calcium and Vitamin D Repletion in Patients After Thyroidectomy

Evaluation of Risk Factors and Clinicopathologic Features for Intrahepatic Cholangiocarcinoma in Southern China: A Possible Role of Hepatitis B Virus

Metallothionein-1 Genotypes in the Risk of Oral Squamous Cell Carcinoma